WEREWOLF THERAPEUTICS, INC. Sublease Income
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Sublease Income of $0 for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. sublease income for the quarter ending 2023-06-30 was $400.00K, a 488.24% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. sublease income for the quarter ending 2023-03-31 was $400.00K.
- WEREWOLF THERAPEUTICS, INC. sublease income for the quarter ending 2022-12-31 was $382.00K.
- WEREWOLF THERAPEUTICS, INC. sublease income for the quarter ending 2022-09-30 was $384.00K.
- WEREWOLF THERAPEUTICS, INC. sublease income for fiscal 2023 was $1.56M, a 87.29% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. sublease income for fiscal 2022 was $834.00K.
- WEREWOLF THERAPEUTICS, INC. sublease income for fiscal 2021 was $0.00.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 S-4 · filed 2026-09-22 | |||
| 2024-12-31 | $398.00K S-4 · filed 2026-09-22 | |||
| 2023-12-31 | $1.56M 10-K · filed 2025-03-11 | |||
| 2023-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $800.00K 10-Q · filed 2023-08-10 | $1.18M derived: sum of 3 quarters · filed 2024-03-07 | $1.57M derived: sum of 4 quarters · filed 2024-03-07 |
| 2023-03-31 | $400.00K 10-Q · filed 2023-05-11 | $782.00K derived: sum of 2 quarters · filed 2024-03-07 | $1.17M derived: sum of 3 quarters · filed 2024-03-07 | $1.23M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $766.00K derived: sum of 2 quarters · filed 2024-03-07 | $834.00K derived: sum of 3 quarters · filed 2024-03-07 | $834.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $384.00K 10-Q · filed 2022-11-10 | $452.00K derived: sum of 2 quarters · filed 2022-11-10 | $452.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $68.00K 10-Q · filed 2022-08-11 | $68.00K 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |